Treatment options in patients with chronic hepatitis C

Canadian Journal of Public Health

Volumn 91, Issue SUPPL. 1, 2000, Pages

  Burak, K W ^a   Lee, S S ^a  

^a 3330 Hospital Dr NW   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2B INTERFERON; AMANTADINE; ANTIVIRUS AGENT; BETA INTERFERON; BILE ACID; ENZYME INHIBITOR; HELICASE; HERBACEOUS AGENT; IMMUNOMODULATING AGENT; LIVER ENZYME; MACROGOL DERIVATIVE; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE ANALOG; OFLOXACIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; RIMANTADINE; RNA HELICASE; SERINE PROTEINASE; TAUROURSODEOXYCHOLIC ACID; THYMOSIN; URSODEOXYCHOLIC ACID; VIRUS PROTEIN; VIRUS RNA;

ARTICLE; CHINESE HERB; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE; HEALTH CARE PLANNING; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DISEASE; MALE; PUBLIC HEALTH; TERATOGENICITY; THYROIDITIS; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-ALPHA; INTERFERON-BETA; RIBAVIRIN;

EID: 0033759224     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Hepatitis C: The clinical spectrum of the disease
2. Management of viral hepatitis: Clinical and public health perspectives - A consensus statement
3. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
4. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials
5. Review article: Interferon and hepatitis C - Factors predicting therapeutic outcome
6. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C
7. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection
8. Hepatitis C in the patient with human immunodeficiency virus infection
9. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy
10. Durability of serological remission in chronic hepatitis C treated with interferon-alpha-2B
11. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C
12. Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C
13. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy
14. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV- related liver cirrhosis
15. Ten year follow-up of patients with chronic hepatitis C treated with interferon
16. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan
17. Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C
18. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha
19. Consensus interferon: A novel interferon for the treatment of hepatitis C
20. Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C
21. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon
22. Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients
23. Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: A pilot study
24. Pilot study of ofloxacin and interferon-alpha combination therapy for chronic hepatitis C without sustained response to initial interferon administration
25. Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: Results of a long-term follow-up trial
26. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: A multicenter placebo-controlled study
27. Review article: Glycyrrhizin as a potential treatment for chronic hepatitis C
28. Hepatitis C: Epidemiology and review of complementary/alternative medicine treatments
29. Combination therapy with thymosin alpha 1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
30. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: Preliminary results
31. Treatment of chronic hepatitis C with amantidine
32. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients
33. A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy
34. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
35. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone
36. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centers
37. Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
38. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
39. Randomized trial of interferon 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
40. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response
41. Cost effectiveness of interferon 2b combined with ribavirin for the treatment of chronic hepatitis C
42. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
43. Re-treatment of chronic hepatitis C with consensus interferon
44. Is an ″A la carte″ combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
45. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α2a (IFN-α2a) to healthy subjects
46. A controlled, randomized, multicenter descending dose phase II trial of pegylated interferon α2a vs standard interferon α2a in patients with chronic hepatitis C
47. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load
48. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders
49. New treatment strategies in non-responder patients with chronic hepatitis C
50. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia
51. Future directions in the treatment of patients with chronic hepatitis C virus infection